WO2000069915A3 - COMBINED APPROACH TO TREATMENT OF CANCER WITH hCG VACCINES - Google Patents

COMBINED APPROACH TO TREATMENT OF CANCER WITH hCG VACCINES Download PDF

Info

Publication number
WO2000069915A3
WO2000069915A3 PCT/US2000/013392 US0013392W WO0069915A3 WO 2000069915 A3 WO2000069915 A3 WO 2000069915A3 US 0013392 W US0013392 W US 0013392W WO 0069915 A3 WO0069915 A3 WO 0069915A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcg
cancer
treatment
combined approach
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/013392
Other languages
French (fr)
Other versions
WO2000069915A2 (en
Inventor
Patrick L Iversen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarepta Therapeutics Inc
Original Assignee
AVI Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AVI Biopharma Inc filed Critical AVI Biopharma Inc
Priority to CA002369397A priority Critical patent/CA2369397A1/en
Priority to JP2000618331A priority patent/JP2003502025A/en
Priority to AU51361/00A priority patent/AU5136100A/en
Priority to EP00935985A priority patent/EP1183275B1/en
Priority to DE60029953T priority patent/DE60029953T2/en
Publication of WO2000069915A2 publication Critical patent/WO2000069915A2/en
Publication of WO2000069915A3 publication Critical patent/WO2000069915A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

The invention relates to an improved method for immunotherapy of cancer by administering to a subject a human anti-hCG monoclonal antibody and/or an hCG immunogenic peptide vaccine, followed by monitoring the patient's immune response to hCG-CTP16, hCG-CTP21 and hCG-CTP37, respectively, and adjusting the vaccination regimen according to the detectable immune response to the hCG immunogenic peptides. The invention further relates to devices, methods and kits for immunoassay of hCG immunogenic peptides.
PCT/US2000/013392 1999-05-17 2000-05-15 COMBINED APPROACH TO TREATMENT OF CANCER WITH hCG VACCINES Ceased WO2000069915A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002369397A CA2369397A1 (en) 1999-05-17 2000-05-15 Combined approach to treatment of cancer with hcg vaccines
JP2000618331A JP2003502025A (en) 1999-05-17 2000-05-15 Combination approach for treatment of cancer with hcG vaccine
AU51361/00A AU5136100A (en) 1999-05-17 2000-05-15 Combined approach to treatment of cancer with hcg vaccines
EP00935985A EP1183275B1 (en) 1999-05-17 2000-05-15 Specific antibodies against human chorionic gonadotropin and their use in therapy and diagnostic
DE60029953T DE60029953T2 (en) 1999-05-17 2000-05-15 Specific antibodies against human chorionic gonadotropin and their use in therapy and diagnosis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13443299P 1999-05-17 1999-05-17
US13441999P 1999-05-17 1999-05-17
US60/134,432 1999-05-17
US60/134,419 1999-05-17

Publications (2)

Publication Number Publication Date
WO2000069915A2 WO2000069915A2 (en) 2000-11-23
WO2000069915A3 true WO2000069915A3 (en) 2001-07-26

Family

ID=26832312

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013392 Ceased WO2000069915A2 (en) 1999-05-17 2000-05-15 COMBINED APPROACH TO TREATMENT OF CANCER WITH hCG VACCINES

Country Status (10)

Country Link
US (1) US6764680B2 (en)
EP (1) EP1183275B1 (en)
JP (1) JP2003502025A (en)
KR (1) KR100684573B1 (en)
AT (1) ATE335764T1 (en)
AU (1) AU5136100A (en)
CA (1) CA2369397A1 (en)
DE (1) DE60029953T2 (en)
ES (1) ES2269150T3 (en)
WO (1) WO2000069915A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294171B2 (en) * 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
EP1644048B1 (en) 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2005005465A2 (en) * 2003-07-08 2005-01-20 Board Of Regents, University Of Texas System Methods and compositions to enhance immune responses via recall antigens
CA2538300A1 (en) * 2003-09-22 2005-03-31 Green Peptide Co., Ltd. Prognosis in cancer patients vaccinated with a cancer antigen peptide-associated agent
US8119174B2 (en) * 2004-04-26 2012-02-21 General Mills Ip Holdings Ii, Llc Low sugar presweetened dry coated cereals and method of preparation
KR100881043B1 (en) * 2004-06-03 2009-01-30 에프. 호프만-라 로슈 아게 Treatment with oxaliplatin and EVFR inhibitors
EP1773402A2 (en) * 2004-06-17 2007-04-18 Mannkind Corporation Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods
JP2006248978A (en) 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
CA2615460A1 (en) * 2005-08-08 2007-02-15 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
AR059922A1 (en) * 2006-04-01 2008-05-07 Galaxy Biotech Llc HUMANIZED MONOCLONAL ANTIBODIES FOR THE GROWTH FACTOR OF HEPATOCITS
CN101314619B (en) * 2007-06-01 2010-12-22 齐鲁制药有限公司 Tumor therapeutic vaccine CTP37CRM197 immunogen and its preparation method and application
EP2252285B1 (en) * 2008-01-18 2015-04-15 Horphag Research Ip (Mir) Ltd. Abnormal intraocular pressure treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4691006A (en) 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
WO1984004598A1 (en) * 1983-05-06 1984-11-22 Univ Columbia Immunoassay for human chorionic gonadotropin
US6319504B1 (en) * 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIRNHOFER S ET AL: "THE MOLECULAR BASIS FOR EPITOPES ON THE FREE BETA-SUBUNIT OF HUMAN CHORIONIC GONADOTROPHIN (HCG), ITS CARBOXYL-TERMINAL PEPTIDE AND THE HCGBETA-CORE FRAGMENT", JOURNAL OF ENDOCRINOLOGY,GB,BRISTOL, vol. 141, no. 1, 1 April 1994 (1994-04-01), pages 153 - 162, XP000609254, ISSN: 0022-0795 *
SNYDER, LAURA L. ET AL: "Synthetic hormone/growth factor subunit vaccine with application to antifertility and cancer", PHARM. BIOTECHNOL. (1995), 6(VACCINE DESIGN), 907-30, XP000944649 *
TALWAR G P: "Vaccines for control of fertility and hormone-dependent cancers.", IMMUNOLOGY AND CELL BIOLOGY, (1997 APR) 75 (2) 184-9., XP000944872 *
TRIOZZI P L ET AL: "Effects of a beta-human chorionic gonadotropin subunit immunogen administered in aqueous solution with a novel nonionic block copolymer adjuvant in patients with advanced cancer.", CLINICAL CANCER RESEARCH, (1997). 3 (12 PT. 1), PP. 2355-62. JOURNAL CODE: C2H. ISSN: 1078-0432., The Ohio State University Comprehensive Cancer Center, 410 West 10th Ave, Columbus, Ohio 43210, USA., XP000941669 *

Also Published As

Publication number Publication date
JP2003502025A (en) 2003-01-21
CA2369397A1 (en) 2000-11-23
AU5136100A (en) 2000-12-05
US6764680B2 (en) 2004-07-20
US20020164338A1 (en) 2002-11-07
ATE335764T1 (en) 2006-09-15
KR100684573B1 (en) 2007-02-20
DE60029953D1 (en) 2006-09-21
WO2000069915A2 (en) 2000-11-23
KR20020007416A (en) 2002-01-26
EP1183275B1 (en) 2006-08-09
ES2269150T3 (en) 2007-04-01
DE60029953T2 (en) 2007-09-13
EP1183275A2 (en) 2002-03-06

Similar Documents

Publication Publication Date Title
IL142948A0 (en) Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
RU95105991A (en) Conjugate, vaccine, methods of immunogenicity enhancement, methods of immunization
WO2000069915A3 (en) COMBINED APPROACH TO TREATMENT OF CANCER WITH hCG VACCINES
WO1995029193A3 (en) Melanoma antigens
PL392964A1 (en) Hyperimmune serum reactive antigen, the use of this antigen for the production of a pharmaceutical formulation, fragment of the hiperimmune antigen, antigen auxiliary epitopes, a vaccine containing the hyperimmune serum reactive antigen, formulation containing antibodies, process for the preparation of this formulation, the use of the formulation for the treatment of staphylococcal infections, and screening method
NZ512574A (en) Novel streptococcus antigens useful as vaccines
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
AU1227295A (en) Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma
SI1270595T1 (en) Anti ccr4 antibody and its fragment
GB9818627D0 (en) Improvements in dva vaccination
WO2001082963A3 (en) Method of identifying and producing antigen peptides and use thereof as vaccines
ATE267258T1 (en) VACCINES FOR THE RESPIRATORY SYNZYTIAL VIRUS WITH NUCLIC ACIDS
Jemmerson et al. Mapping antigenic sites on proteins: Implications for the design of synthetic vaccines.
AU2002245756A1 (en) Identification and modification of immunodominant epitopes in polypeptides
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
IL126803A0 (en) Method and composition for reconforming multi-epitopic antigens to initiate an immune response
IL144265A0 (en) Use of antibodies for the vaccination against cancer
WO2001079259A8 (en) Javelinization of protein antigens to heat shock proteins
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
EP2193804A3 (en) Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens
AU4803785A (en) Cross-reactive and protective epitopes of circumsporozoite proteins
AU3693897A (en) Melanoma associated peptide analogues and vaccines against melanoma
WO2002060390A3 (en) Induction of immune responses to isoaspartyl-modified antigens
Wang et al. Gene conjugation of molecular adjuvant C3d3 to hCGβ increased the anti‐hCGβ Th2 and humoral immune response in DNA immunization
AU2002324486A1 (en) Mutants of clostridium septicum alpha toxin and vaccines, antibodies, sera, and methods of treatment therewith

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2369397

Country of ref document: CA

Ref document number: 2369397

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 618331

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017014692

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 51361/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000935985

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000935985

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2000935985

Country of ref document: EP